Used in pharmaceutical research as a key intermediate in the synthesis of DPP-IV (Dipeptidyl Peptidase-4) inhibitors, particularly in the development of antidiabetic agents for type 2 diabetes. Its structure supports high selectivity and binding affinity to the DPP-IV enzyme active site, which plays a role in blood sugar regulation. This makes it valuable in drug design to enhance insulin secretion after meals, reduce hepatic glucose production, and avoid hypoglycemia. The compound’s chiral centers and functional groups allow for precise stereochemical control during synthesis, enhancing the efficacy and safety of final drug products. Currently under laboratory investigation and not yet approved for clinical use.